Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000950170-25-034674
Filing Date
2025-03-06
Accepted
2025-03-06 16:17:27
Documents
1
Period of Report
2025-03-04

Document Format Files

Seq Description Document Type Size
1 4 ownership.html 4  
1 4 ownership.xml 4 3792
  Complete submission text file 0000950170-25-034674.txt   5453
Mailing Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421
Business Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421 781-761-4904
Aldeyra Therapeutics, Inc. (Issuer) CIK: 0001341235 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O EVOKE PHARMA, INC. 505 LOMAS SANTA FE DRIVE SOLANA BEACH CA 92075
Business Address
Brady Todd C (Reporting) CIK: 0001579179 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-36332 | Film No.: 25715489